| $350M | ||
| $217M | ||
| $172M | ||
| $109M | ||
| $107M | ||
| $104M |
Buys | $1,342,385 | 5 | 100 |
Sells | $0 | 0 | 0 |
| de Boer Daniel Anton | Chief Executive Officer | 3 | $853,460 | 0 | $0 | $853,460 |
| Filius Bart | director | 2 | $488,925 | 0 | $0 | $488,925 |
ProQR Therapeutics N.V. operates as a biopharmaceutical enterprise dedicated to discovering and developing RNA-based therapies designed to address genetic disorders. The company's pipeline includes two primary drug candidates in advanced clinical stages: Sepofarsen is currently in a Phase II/III clinical trial, known as the ILLUMINATE trial, targeting Leber Congenital Amaurosis 10 (LCA10). Ultevursen is also undergoing Phase II/III evaluation for the treatment of USH2A-mediated retinitis pigmentosa and Usher syndrome. Beyond its clinical …
Over the last 12 months, insiders at ProQR Therapeutics N.V. have bought $1.34M and sold $0 worth of ProQR Therapeutics N.V. stock.
On average, over the past 5 years, insiders at ProQR Therapeutics N.V. have bought $1.34M and sold $0 worth of stock each year.
Highest buying activity among insiders over the last 12 months: de Boer Daniel Anton (Chief Executive Officer) — $853,460. Filius Bart (director) — $488,925.
The last purchase of 200,000 shares for transaction amount of $353,960 was made by de Boer Daniel Anton (Chief Executive Officer) on 2026‑07‑31.
| 2026-07-31 | de Boer Daniel Anton | Chief Executive Officer | 200,000 0.1953% | $1.77 | $353,960 | +6.40% | ||
| 2026-07-17 | Filius Bart | director | 150,000 0.1441% | $1.72 | $257,925 | +5.00% | ||
| 2026-07-09 | de Boer Daniel Anton | Chief Executive Officer | 150,000 0.1408% | $1.74 | $261,000 | 0.00% | ||
| 2026-07-07 | de Boer Daniel Anton | Chief Executive Officer | 150,000 0.1364% | $1.59 | $238,500 | +6.02% | ||
| 2026-06-26 | Filius Bart | director | 150,000 0.1433% | $1.54 | $231,000 | +15.03% |
| Increased Positions | 34 | +57.63% | 5M | +13.53% |
| Decreased Positions | 19 | -32.2% | 5M | -14.3% |
| New Positions | 10 | New | 861,714 | New |
| Sold Out Positions | 9 | Sold Out | 2M | Sold Out |
| Total Postitions | 74 | +25.42% | 37M | -0.77% |